• search hit 15 of 129
Back to Result List

7,8-Dihydroxyflavone is a direct inhibitor of pyridoxal phosphatase

Please always quote using this URN: urn:nbn:de:bvb:20-opus-350446
  • Vitamin B6 deficiency has been linked to cognitive impairment in human brain disorders for decades. Still, the molecular mechanisms linking vitamin B6 to these pathologies remain poorly understood, and whether vitamin B6 supplementation improves cognition is unclear as well. Pyridoxal phosphatase (PDXP), an enzyme that controls levels of pyridoxal 5’-phosphate (PLP), the co-enzymatically active form of vitamin B6, may represent an alternative therapeutic entry point into vitamin B6-associated pathologies. However, pharmacological PDXPVitamin B6 deficiency has been linked to cognitive impairment in human brain disorders for decades. Still, the molecular mechanisms linking vitamin B6 to these pathologies remain poorly understood, and whether vitamin B6 supplementation improves cognition is unclear as well. Pyridoxal phosphatase (PDXP), an enzyme that controls levels of pyridoxal 5’-phosphate (PLP), the co-enzymatically active form of vitamin B6, may represent an alternative therapeutic entry point into vitamin B6-associated pathologies. However, pharmacological PDXP inhibitors to test this concept are lacking. We now identify a PDXP and age-dependent decline of PLP levels in the murine hippocampus that provides a rationale for the development of PDXP inhibitors. Using a combination of small molecule screening, protein crystallography and biolayer interferometry, we discover and analyze 7,8-dihydroxyflavone (7,8-DHF) as a direct and potent PDXP inhibitor. 7,8-DHF binds and reversibly inhibits PDXP with low micromolar affinity and sub-micromolar potency. In mouse hippocampal neurons, 7,8-DHF increases PLP in a PDXP-dependent manner. These findings validate PDXP as a druggable target. Of note, 7,8-DHF is a well-studied molecule in brain disorder models, although its mechanism of action is actively debated. Our discovery of 7,8-DHF as a PDXP inhibitor offers novel mechanistic insights into the controversy surrounding 7,8-DHF-mediated effects in the brain.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Marian BrennerORCiD, Christoph Zink, Linda Witzinger, Angelika Keller, Kerstin Hadamek, Sebastian BotheORCiD, Martin Neuenschwander, Carmen VillmannORCiD, Jens Peter von Kries, Hermann SchindelinORCiD, Elisabeth Jeanclos, Antje GohlaORCiD
URN:urn:nbn:de:bvb:20-opus-350446
Document Type:Preprint
Faculties:Medizinische Fakultät / Institut für Klinische Neurobiologie
Medizinische Fakultät / Institut für Pharmakologie und Toxikologie
Fakultät für Biologie / Rudolf-Virchow-Zentrum
Language:English
Parent Title (English):eLife
Year of Completion:2024
Source:eLife (2024) DOI: 10.7554/eLife.93094.2
DOI:https://doi.org/10.7554/eLife.93094.2
Dewey Decimal Classification:5 Naturwissenschaften und Mathematik / 57 Biowissenschaften; Biologie / 572 Biochemie
6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:7,8-dihydroxyflavone (7,8-DHF); PDXP inhibitors; pyridoxal phosphatase (PDXP); vitamin B6
Release Date:2024/05/28
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International